In 1998, Sysmex entered into a Global Collaboration Agreement with Roche for mutual sales of their products, and cooperation between their respective R&D and IT businesses. In the 25 years since, the two companies have built a solid partnership through an evolution of their relationship in response to environmental changes and complementing each other, such as in product portfolios and sales and service networks. More recently, in 2020, the two companies signed the GBPA to define the collaborative framework between the two.1
In recent years, clinical laboratories have been facing increasingly diverse and complex challenges. These challenges include the need for healthcare efficiency and quality improvement driven by factors such as aging population and advancements in medical technology. Additionally, there is a growing demand to strengthen the healthcare infrastructure in response to the spread of COVID-19 infections. Also, there are increasing expectations on companies to help solve social issues, such as climate change, environmental issues, and disparities in healthcare to realize a sustainable society.
Sysmex has agreed with Roche to expand the scope of their collaboration to include not only their products and sales and services, but also the creation of a circular resource value chain in the in vitro diagnostics domain to deliver greater value to customers in laboratories from an “eco-social” perspective, which aims to strengthen the links between corporate activities and solutions to social issues.
“We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration. Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society,” said Kaoru Asano, President of Sysmex Corporation.
“We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions. Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow,” said Matt Sause, CEO of Roche Diagnostics.
Going forward, Sysmex will endeavor to continue providing high-value products and services that exceed customer expectations, while creating new value toward solving social issues, through collaboration with Roche over the medium- to long-term, which involves sharing their individual management resources and complementing supply chains.
About Sysmex Corporation
In line with its mission of “shaping the advancement of healthcare,” which is defined in the “Sysmex Way,” the corporate philosophy of the Sysmex Group, Sysmex works to contribute to the development of healthcare and the healthy lives of people. Sysmex currently operates in more than 190 countries and regions and holds the position of global market leader in hematology. Also, with a view to realizing a sustainable society, Sysmex set “reducing environmental impact” as a priority issue to address, and in May 2023 formulated “Sysmex Eco-Vision 2033”.2 The Company envisions to collaboratively create innovative solutions that will advance the realization of a circular society by taking on the challenge of green innovation and utilizing Sysmex's strengths.